| Bioactivity | rel-Lifirafenib (rel-BGB-283) is the relative configuration of Lifirafenib (HY-18957). Lifirafenib is a potent Raf Kinase and EGFR inhibitor[1]. |
| Name | rel-Lifirafenib |
| CAS | 1446090-77-2 |
| Formula | C25H17F3N4O3 |
| Molar Mass | 478.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tang Z, et al. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97. |
rel-Lifirafenib
CAS: 1446090-77-2 F: C25H17F3N4O3 W: 478.42
rel-Lifirafenib (rel-BGB-283) is the relative configuration of Lifirafenib (HY-18957). Lifirafenib is a potent Raf Kinas
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.